Navio MD vs bmiMD
An in-depth comparison of two leading GLP-1 Providers
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Navio MD
Best for: moving between compounded and brand without changing seller
Visit Navio MD →
Two GLP-1 Providers chasing the same patients, trading off price, geography and what lands in the box differently. On our scoring, bmiMD opens cheaper — $99/mo against $189, and bmiMD finishes ahead, 9.1 to 8.3. What follows: the prices, what each plan actually covers, the six-dimension score, where each one is weak, and who should pick which.
Pricing
Navio MD
as low as $189/mo; tiered by dose
as low as $345/mo; brand price varies by dose
as low as $445/mo; tiered by dose
as low as $1,249/mo; tiered by dose
Ozempic as low as $345/mo (compounded tirzepatide $189/mo also offered)
bmiMD
Ladder by plan length: 12 mo $99/mo (Total $1,188.00), 6 mo $109/mo, 3 mo $119/mo, 1 mo $129/mo. 'Same price at every dose'; provider visit + free shipping included. Verified 2026-07-14 at bmimd.com/personalized-glp-1/ and /semaglutide-injection/.
Ladder by plan length: 12 mo $139/mo (Total $1,668.00), 6 mo $149/mo, 3 mo $159/mo, 1 mo $179/mo. Same flat-dose model. Verified 2026-07-14 at bmimd.com/tirzepatide-injection/.
Strike-through pricing shown: $151.20 -> $99/mo (12-mo) up to $199.80 -> $129/mo (monthly), labeled 'Limited time offer'. bmimd.com/glp-1-microdose/.
Strike-through pricing shown: $250.20 -> $139/mo (12-mo) up to $299.70 -> $179/mo (monthly), labeled 'Limited time offer'. bmimd.com/glp-1-gip-microdose/.
What’s included
Navio MD
Inclusions not disclosed.
bmiMD
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Score breakdown
Both providers are scored on the same six-dimension framework. The gradient bar marks the stronger side on each dimension.
Navio MD
8.3/10
bmiMD
9.1/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
Features & Coverage
| Feature | Navio MD | bmiMD |
|---|---|---|
| Starting Price | $189/mo | ✓$99/mo |
| Features | ✓6 features | 2 features |
| States Available | 48 | ✓50 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
About Navio MD
NavioMD sells compounded tirzepatide at $247/mo plus brand-name Ozempic at $1,199/mo and Mounjaro at $1,249/mo. It is LegitScript verified and available in 48 states, not AL or MS. The price is the same at every dose. It also offers women's hormone optimization.
Read our full Navio MD review →About bmiMD
bmiMD is a medical weight loss clinic that prescribes GLP-1 medications through telehealth.
Read our full bmiMD review →Pros & Cons
Navio MD
What we like
- Semaglutide at $345 a month, 73% below the $1299 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- Coverage is published for 48 states
- No FDA warning letter matched this operator when we searched our enforcement register
Watch-outs
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its tirzepatide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality
bmiMD
What we like
- Semaglutide at $99 a month, 48% below the $189 median for the same drug and form across this register
- Tirzepatide at $139 a month, 48% below the $267 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers medication, consult, shipping
- Coverage is published for all 50 states
- No FDA warning letter matched this operator when we searched our enforcement register
Watch-outs
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
bmiMD takes it, 9.1 against 8.3, and it is especially strong on starting below a standard dose, with microdose tiers. Navio MD is no weak second and may fit you better on moving between compounded and brand without changing seller.
Choose Navio MD if…
You want moving between compounded and brand without changing seller and an opening price near $189 a month.
Choose bmiMD if…
You want starting below a standard dose, with microdose tiers and an opening price near $99 a month.
Ready to start? Vetted GLP-1 providers
Vetted telehealth providers that prescribe GLP-1 online.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Found
Tirzepatide at $169/month, 37% under the register median
From $99/mo
Get started →Telos Rx
Starting below a standard dose, with microdose tiers
From $49/mo
Get started →MyDrHank
An oral route if you will not self-inject
From $25/mo
Get started →Navio MD vs bmiMD: FAQ
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Related comparisons
Continue exploring Navio MD and bmiMD head-to-heads in the same category.
- Navio MD vs Trimi Health
- Navio MD vs Embody
- Navio MD vs He & She MD
- bmiMD vs Lean Meds
- bmiMD vs NextMeds
- bmiMD vs CoreAge Rx
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.